iSelect Fund
  • Portfolio
  • Team
  • Focus Areas
    • Food & Agriculture
    • Healthcare
    • Food is Health
    • Soil Health
    • Impact Investing
    • Entrepreneurs
  • Invest
  • Insights
  • Contact
  • My iSelect
    • My iSelect Login
Select Page

Machine Learning Will Transform Medicine, but Only if We Use it Right

Read more

Analytical Validation of Cofactor Genomics’ Immune Profiling Assay Published in Journal of Molecular Diagnostics

Read more

New Study Shows Predictive Immune Modeling from Cofactor Genomics is Superior to PD-L1 Assays in Predicting Patient Response to Anti-PD-1 Therapy

Read more

Why RNA?

Read more

Cofactor Genomics Expands Leadership Team and Opens New Boston Predictive Immune Modeling CenterCofactor Genomics Expands Leadership Team and Opens New Boston Predictive Immune Modeling Center

Read more

Top 20 Biotech Companies – 2019

Read more
« Older Entries
Next Entries »

Related Posts

  • cancer
    2 Companies That Are Working to Cure Cancer Right Now
  • invest outside Silicon Valley
    The Role of Diversification in Venture Investing
  • Cofactor Genomics
    [PODCAST] Cofactor Genomics and the Future of Personalized Medicine
  • Gene Editing
    Don’t Worry Dad, We Are Just Editing Our Genes  
  • DNA
    Cofactor Genomics: RNA Is About to Make Personalized Medicine a Reality
AgTechFund BLOG SIDEBAR

(314) 219-8688

7750 Maryland Ave
Box 11826
St. Louis, MO 63105

Crunchbase   Twitter   LinkedIn   Facebook   YouTube

Securities offered through North Capital Private Securities ("NCPS"), Member FINRA/SIPC, located at 623 East Ft. Union Blvd, Suite 101, Salt Lake City, UT 84047. NCPS does not make investment recommendations and no communication, through this website or in any other medium should be construed as a recommendation for any security offered on or off this investment platform.  Please review North Capital’s Form CRS and its background on FINRA’s BrokerCheck.  Investments in private offerings are speculative, illiquid and involve a high degree of risk and those investors who cannot afford to lose their entire investment and who cannot hold an investment for an indeterminate period should not invest in such offerings. Past performance is not indicative of future results.  All information provided herein should not be relied upon to make an investment decision and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Prospective investors are recommended to consult with a financial adviser, attorney, accountant, and any other professional that can help you understand and assess the risks associated with an investment opportunity. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.